Brief: Blueprint Medicines - Genentech Announced Voluntary Withdrawal Of US Indication Of GAVRETO

Blueprint Medicines

30/06/2023 11:34

June 30 (Reuters) - Blueprint Medicines Corp  BPMC.O :
    * BLUEPRINT MEDICINES - GENENTECH ANNOUNCED VOLUNTARY
WITHDRAWAL
OF U.S. INDICATION OF GAVRETO
    * BLUEPRINT MEDICINES - GENENTECH STATED DECISION TO
WITHDRAW
INDICATION NOT DUE TO NEW SAFETY/EFFICACY DATA FOR GAVRETO OR
PRODUCT SAFETY/QUALITY ISSUE
    * BLUEPRINT MEDICINES - UNDER CO'S COLLABORATION, GENENTECH
REMAINS NEW DRUG APPLICATION SPONSOR IN UNITED STATES
    * BLUEPRINT MEDICINES CORP - ACCELERET-MTC TRIAL WILL NO
LONGER BE
PURSUED DUE TO FEASIBILITY
    * BLUEPRINT MEDICINES - CONFIRMATORY STUDIES TO MEET
COMMITMENTS
REQUIRED TO CONVERT REMAINING INDICATIONS FOR GAVRETO TO FULL
APPROVAL, ARE ONGOING
    * BLUEPRINT MEDICINES - ANTICIPATES GENENTECH'S DECISION
WILL HAVE
NO IMPACT TO ITS 2023 COLLABORATION REVENUE GUIDANCE OF $40 TO
$50 MILLION
    * BLUEPRINT MEDICINES-GENENTECH'S VOLUNTARY WITHDRAWAL OF
U.S.
INDICATION OF GAVRETO FOR TREATMENT OF SOME PATIENTS WITH MUTANT
MEDULLARY THYROID CANCER
    * BLUEPRINT MEDICINES - GENENTECH STATED OTHER APPROVED
INDICATIONS FOR GAVRETO IN U.S. ARE UNAFFECTED

Further company coverage:  BPMC.O 

 ((reuters.briefs@thomsonreuters.com;))